Theriva Biologics, Inc. Quarterly Deferred Income Tax Liabilities, Net in USD from Q1 2022 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.
Summary
Theriva Biologics, Inc. quarterly Deferred Income Tax Liabilities, Net history and growth rate from Q1 2022 to Q3 2023.
  • Theriva Biologics, Inc. Deferred Income Tax Liabilities, Net for the quarter ending September 30, 2023 was $413K, a 79.2% decline year-over-year.
Deferred Income Tax Liabilities, Net, Quarterly (USD)
Deferred Income Tax Liabilities, Net, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2023 $413K -$1.57M -79.2% Sep 30, 2023 10-Q 2023-11-13
Q2 2023 $952K -$1.34M -58.5% Jun 30, 2023 10-Q 2023-08-08
Q1 2023 $1.31M -$2.42M -64.8% Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $1.62M Dec 31, 2022 10-K 2024-03-25
Q3 2022 $1.98M Sep 30, 2022 10-K 2023-03-30
Q2 2022 $2.29M Jun 30, 2022 10-K 2023-03-30
Q1 2022 $3.73M Mar 31, 2022 10-Q 2022-05-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.